Insight

The impact of post-remission G-CSF use in the phase 3 studies of venetoclax in AML

Courtney D. DiNardo/faculty.mdanderson.org

Dec 6, 2024, 15:22

The impact of post-remission G-CSF use in the phase 3 studies of venetoclax in AML

Mohamed Benlazar, Professor of Hematology at Sidi Bel Abbès University Hospital, shared a post on X:

“The impact of post-remission G-CSF use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed AML |American Journal of Hematology | Blood Research Journal | Wiley Online Library.”

The impact of post-remission granulocyte colony-stimulating factor use in the phase 3 studies of venetoclax combination treatments in patients with newly diagnosed acute myeloid leukemia

Authors: Courtney D. DiNardo, Keith W. Pratz, Panayiotis Panayiotidis, Xudong Wei, Vladimir Vorobyev, Árpád Illés, Inho Kim, Vladimir Ivanov, Grace Ku, Catherine L. Miller, Meng Zhang, Fernando Tatsch, Jalaja Potluri, Xenia Schmidt, Christian Récher

venetoclax

Árpád Illés cancer Catherine L. Miller Christian Récher Courtney D. DiNardo Fernando Tatsch Grace Ku Inho Kim Jalaja Potluri Keith W. Pratz Meng Zhang OncoDaily Oncology Panayiotis Panayiotidis venetoclax Vladimir Ivanov Vladimir Vorobyev Xenia Schmidt Xudong Wei

In Memory of Alan Rickman and His Battle with Prostate and Pancreatic Cancer

New Paper Alert: Systemic management of advanced HCC: an increasingly complex game

AC-satoreotide got FDA Orphan Drug Designation status for SCLC and MCC

Oncologist Near Me – Nazik Hammad: A Leader in Cancer Care, Medical Education, and Health Equity

Garo Armen - A Bold Call to Action: Embracing Real-Time Innovation in Pediatric Cancer